As a result, this finding will not be included in the CCDS but included in local labels, such as the Summary of Product Characteristics (SmPC) or U.S. Prescribing Information (USPI). These differences ...

– Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy ® plus Keytruda ® in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer – FOSTER CITY, Calif.

USPI is turning its focus to AI for 2025. At the end of 2024, its parent company, Tenet, launched Commure’s ambient AI platform across its physician network. Tenet Physician Resources will have access ...